All In Biotech

Drug Trial Radar · NCT00911326

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

101

Actual

Start

May 2009

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Navidea BiopharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the false negative rate (FNR) associated with Lymphoseek-identified sentinel lymph nodes (SLNs) relative to the pathological status of non-sentinel lymph nodes in elective neck dissection (END) in head \& neck squamous cell carcinoma (HNSCC). NEO3-06 (this study) is a Phase 3 clinical trial designed to supplement NEO3-05, a completed Phase 3 clinical trial conducted in patients with breast cancer or melanoma. NEO3-05 was designed to establish Lymphoseek as an effective radio-diagnostic agent to be used in the intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

  • LymphoseekDrug

    Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. False Negative Rate (FNR)Time frame: Surgery after injection of Lymphoseek

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama, Birmingham

    Birminham, Alabama

  • Moores UCSD Cancer Center

    La Jolla, California

  • San Diego VA Hospital

    San Diego, California

  • University of Miami, Sylvester Comprehensive Cancer Center

    Miami, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • University of Mississippi

    Jackson, Mississippi

  • University of Missouri-Ellis Fischel Cancer Center

    Columbia, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • Duke University Medical Center

    Durham, North Carolina

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • MD Anderson

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.